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Available online 10 January 2012Background: To study the clinical relevance of type of comorbidity and number of comorbid dis-
orders in anxiety disorders. Four groups were compared according to sociodemographic-,
vulnerability- and clinical factors: single anxiety disorder, anxiety–anxiety comorbidity, anxi-
ety–depressive comorbidity and “double” comorbidity (i.e. anxiety and depressive comorbidity).
Methods:Data were obtained from the Netherlands Study of Anxiety and Depression (NESDA). A
sample of 1004 participants with a current anxiety disorder was evaluated.
Results: As compared with single anxiety, anxiety–anxiety comorbidity was associated with
higher severity, greater chronicity andmore treatment. Anxiety–anxiety comorbidity was associ-
ated with an earlier age of onset and a more chronic course compared with anxiety–depressive
comorbidity, while anxiety–depressive comorbidity was associated with more severe symptoms
andmore impaired functioning than anxiety–anxiety comorbidity. “Double” comorbidity was as-
sociated with higher severity, greater chronicity, more treatment and increased disability. Socio-
demographic and vulnerability factors were comparable among the four groups.
Limitations
A prospective design would be more appropriate to study the outcome. In this study no distinc-
tion was made between whether depression or anxiety disorder preceded the current anxiety
disorder.
Conclusions: It is clinical relevant to diagnose and treat comorbidity among anxiety disorders as it
is associatedwith higher severity andmore chronicity.Whereas anxiety–anxiety comorbidity has
an earlier age of onset and a more chronic course, anxiety–depressive comorbidity leads to more
treatment and impaired functioning. “Double” comorbidity leads to even more severity, chronic-
ity and impairment functioning compared with both anxiety–anxiety and anxiety–depressive
comorbidity.
© 2011 Elsevier B.V. Open access under the Elsevier OA license.Keywords:
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Comorbidityie Veldwijk, Afdeling
etherlands. Tel.: +31
66 686.
Sevink).
ier OA license.1. Introduction
Comorbidity in anxiety disorders represents the rule rather
than the exception. Lifetime comorbidity in patients with anxi-
ety disorders occurs in more than 80% (Brown et al., 2001). The
prevalence of having a current comorbid axis I disorder is
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ders being the most prevalent comorbid disorders (Brown
and Barlow, 1995; Brown et al., 2001).
Comorbidity between anxiety disorders and depressive
disorders has been widely investigated. Anxiety–depressive
comorbidity has been associated with sociodemographic fac-
tors such as female gender, not having a partner, lower socio-
economic status and lower educational level (Alonso et al.,
2004; de Graaf et al., 2002; Fichter et al., 2010); with vulner-
ability factors such as parental psychiatric history, childhood
trauma, negative life events and neuroticism (de Graaf et al.,
2002); and with clinical factors including younger age of
onset (Fichter et al., 2010), illness severity, poorer outcome
(Angst and Vollrath, 1991; Merikangas et al., 2003; Rush et
al., 2005), higher healthcare utilization (Kessler et al., 1994)
and impaired functioning (Fichter et al., 2010; Kessler and
Frank, 1997).
Although anxiety–anxiety comorbidity occurs as fre-
quently as anxiety–depressive comorbidity, it has received
surprisingly little attention to-date. Fragmentized research
suggests that, compared with single anxiety disorders,
patients with anxiety–anxiety comorbidity suffer from more
severe anxiety symptoms (van Balkom et al., 2008). In
addition, anxiety–anxiety comorbidity may be associated
with lower levels of extraversion and higher levels of neurot-
icism (Chambers et al., 2004). Finally, individuals with
anxiety–anxiety comorbidity more frequently report a histo-
ry of childhood abuse (Cougle et al., 2010). However,
anxiety–anxiety comorbidity may not be associated with
lower levels of functioning compared with single anxiety
disorders (Barrera and Norton, 2009; Grant et al., 2005;
Norberg et al., 2008).
Given the lack of data regarding anxiety–anxiety comor-
bidity, further research is needed. It is important to deter-
mine whether it is clinically relevant to diagnose type of
comorbidity and number of comorbid disorders in anxiety
disorders so as to be able to identify patients at a high risk
for developing a comorbid disorder and to direct treatment
at the disorders present.1.1. Aims of the study
Using data from the Netherlands Study of Anxiety and
Depression (NESDA), the clinical relevance of (i) type of co-
morbidity and (ii) number of comorbid disorders in a clini-
cal sample suffering from anxiety disorders was studied.
Four groups were compared: single anxiety disorder,
anxiety–anxiety comorbidity, anxiety–depressive comor-
bidity and “double” comorbidity (i.e. anxiety and depressive
comorbidity). We investigated sociodemographics, vulnera-
bility factors and clinical characteristics to determine
whether:
1) anxiety–anxiety comorbidity differs from a single anxiety
disorder
2) anxiety–anxiety comorbidity differs fromanxiety–depressive
comorbidity (type of comorbidity)
3) “double” comorbidity differs from anxiety–anxiety co-
morbidity and from anxiety–depressive comorbidity
(number of comorbid disorders).2. Methods
2.1. Procedure
Data were obtained from the Netherlands Study of
Depression and Anxiety (NESDA). NESDA is a longitudinal co-
hort study including 2981 adults (18–65 years) with anxiety
disorders (panic disorder with or without agoraphobia, social
phobia, generalized anxiety disorder (GAD) and agoraphobia
without a history of panic disorder) and/or depressive disor-
ders (major depressive disorder, dysthymic disorder) and
healthy controls. A detailed description of the NESDA study
design can be found elsewhere (Penninx et al., 2008). In
short: the NESDA study aims to describe the long-term
course and consequences of depressive and anxiety disorders
in a sample recruited from the community, primary care set-
tings and specialized mental health care facilities. Specific
phobias, post-traumatic stress disorders and obsessive–
compulsive disorders were not assessed and were therefore
not included in this study. Approval of the study was
granted by the Ethical Review Boards of all the participating
centers and written informed consent was obtained from
all participants. For the present study we used data from
the baseline interview, which included a 4-hour interview,
a medical assessment, computer tasks and two self-
administered questionnaires, all instruments were in Dutch.
2.2. Sample
Of the 2981 participants in the baseline interview, 1363
had had at least one 12-month anxiety disorder. To avoid
the confounding of comorbid alcohol dependence, 279 par-
ticipants with a 12-month diagnosis of alcohol dependence
were excluded. Since our research questions regard both
type and number of comorbid disorders, we formed four mu-
tually exclusive groups based on those two aspects: partici-
pants with a single anxiety disorder, without a depressive
disorder (29.4%, n=295), with two anxiety disorders, with-
out a depressive disorder (10.5%, n=105), with one anxiety
disorder and one depressive disorder (29.1%, n=292) and
with “double” comorbidity (i.e. two anxiety disorders and
one or two depressive disorders, 31.1%, n=312). In addition,
18 patients with three anxiety disorders were excluded, as
well as 62 with one anxiety disorder and two depressive dis-
orders. This resulted in a total sample size of 1004.
2.3. Assessment of psychopathology
To diagnose DSM-IV anxiety disorders and depressive
disorders in the past 12 months, the Dutch version of the
Composite International Diagnostic Interview (CIDI, version
2.1) was used as a baseline assessment. The CIDI is a valid
and reliable instrument for axis I diagnoses (World Health
Organization, 1997). The CIDI was conducted by trained re-
search staff.
2.4. Correlates of comorbidity
Sociodemographic factors included gender (male/female),
age (in years), education (in years) and partner status
(present/absent).
Table 1
Socio-demographic- and clinical characteristics of the sample (n=1004).
% (n)
Female gender 72.1 (724)
Partner 66.7 (670)
Chronicity 45.3 (455)
Treatment 51.3 (515)
Mean (SD)
Age (years) 41.0 (12.6)
Education (years) 11.7 (3.2)
Age of onset (years) 20.9 (12.3)
Total IDS score 28.3 (12.6)
Total BAI score 17.7 (10.7)
Total FQ score 34.7 (20.1)
Cognitive disability 31.5 (20.9)
Physical disability 18.7 (21.7)
Social disability 32.8 (20.6)
IDS = Inventory of Depressive Symptomatology, BAI = Beck Anxiety
Inventory, FQ = Fear Questionnaire.
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and depressive disorders, childhood trauma, negative life
events and personality traits. A first-degree family history of
anxiety and depressive disorders was assessed using the
family tree method (Fyer and Weissman, 1999). Childhood
trauma was assessed using the second section of the Child-
hood Trauma Interview previously used in the Netherlands
Mental Health Survey and Incidence Study (NEMESIS, de
Graaf et al., 2002). Childhood trauma was considered present
in cases when participants experienced emotional neglect,
psychological abuse or physical abuse on two or more
occasions prior to age 16, or sexual abuse on one or more oc-
casions prior to age 16. Negative life events in the past year
were measured with the List of Threatening Experiences
(Brugha et al., 1985). This list has good reliability and good
validity (Brugha and Cragg, 1990). Finally, personality traits
were measured with the 60-item NEO-FFI personality
questionnaire, which uses 5 dimensions for personality:
neuroticism, extraversion, openness, agreeableness and con-
scientiousness (Costa and MCCrae, 1995). This scale has
proven to be reliable and valid (Costa and MCCrae, 1992).
Clinical characteristics included age of onset (in years),
chronicity of symptoms (yes/no), severity of depressive,
anxiety and avoidance symptoms (assessed as a continuous
variable), treatment (yes/no) and disability (assessed as a
continuous variable). Age of onset was determined with the
CIDI, and the youngest age of onset was used in the case of
comorbidity. The chronicity of symptoms was based on the
Life Chart Interview (Lyketsos et al., 1994) in which the pres-
ence of anxiety and/or depressive symptoms was retrospec-
tively assessed for the preceding 4 years. Symptoms were
defined as chronic when they occurred during more than
50% of the months during the preceding 4 years. The Life
Chart Interview has shown high validity and reliability
(Warshaw et al., 1994). Receiving treatment was defined as
having received antidepressant medication and/or psycho-
therapy. The use of antidepressant medication was deter-
mined on the basis of drug container inspection for all
drugs used in the month before assessment. Use of antide-
pressants was considered positive when taken regularly
(defined as more than 50% of the time/daily for at least
1 month); these included TCAs, SSRIs and SNRIs. Psychother-
apy was defined as more than 5 contacts with a therapist
during the past 6 months. A therapist could be a psychologist,
psychiatrist, psychotherapist, social worker or social psychi-
atric nurse working in general health care or in specialized
mental health care. The frequency of contacts with a thera-
pist was assessed using the Tic-P (Hakkaart-van Roijen,
2002). This is a validated instrument assessing loss of pro-
ductivity at work and health care utilization. The severity of
anxiety symptoms was assessed with the Beck Anxiety
Inventory (BAI, Beck et al., 1988). The BAI is a 21-item self-
report list. It is widely used and has proven to be highly
valid and reliable (Fydrich et al., 1992). The level of avoid-
ance was measured with the Fear Questionnaire (FQ, Marks
and Matthews, 1979), a 15-item self-report list measuring
phobic symptoms that has been proven valid in a Dutch
population (van Zuuren, 1988). To determine the severity
of depressive symptoms the Inventory of Depressive Symp-
tomatology (IDS, Rush et al., 1996) was used. This scale is a
30-item self-report list measuring depressive symptomsthat has proven to be valid and reliable (Trivedi et al., 2004).
Negative consequences in three domains (cognitive, physical
and social disability) were measured with The World Health
Organization Disability Assessment Schedule (WHODAS II).
This is a 36-item instrument that examines disability in six
domains of life during the past 30 days and has proven to be
valid and reliable (Chwastiak and Von Kurff, 2003).
2.5. Statistical analyses
All statistical analyses were conducted with the SPSS sta-
tistical package version 15.0. As described above, the sample
was divided into four mutually exclusive categories: partici-
pants with a single anxiety disorder, with anxiety-anxiety co-
morbidity, with anxiety–depressive comorbidity and with
“double” comorbidity. Bivariate multinomial logistic regres-
sion analyses were conducted to examine the clinical factors
of comorbidity. Dependent on the research question, differ-
ent groups were taken as the reference group. Subsequently,
risk-indicators (sociodemographics and vulnerability factors)
were examined. Both bivariate and multivariate multinomial
logistic regression analyses were conducted. In the multivar-
iate model, we adjusted for all covariates that were signifi-
cant in the bivariate analyses.
3. Results
3.1. Characteristics of the sample
The sociodemographics and clinical characteristics of
the sample are presented in Table 1. The sample was pre-
dominantly female (72.1%). The mean age of onset was
20.9 years (SD: 12.3). Forty-five percent of the sample suf-
fered from chronic symptoms and about half of the sample
had received treatment (51.3%).
3.2. Anxiety–anxiety comorbidity
To investigate whether anxiety–anxiety comorbidity is
associated with various clinical factors and various risk indi-
cators compared with single anxiety disorders, participants
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those with anxiety–anxiety comorbidity (n=105). The re-
sults are presented in Tables 2 and 3.
Participants with anxiety–anxiety comorbidity had an
earlier age of onset than those with a single anxiety disorder
(19.3 versus 23.0 years; OR: 0.73; 95%CI: 0.58–0.93) and a
higher rate of chronicity (53.3% versus 32.2%; OR: 2.41;
95%CI: 1.53–3.79). Participants with anxiety–anxiety comor-
bidity experienced more severe depressive (OR: 1.52;
95%CI: 1.14–2.03), anxiety (OR: 1.58; 95%CI: 1.20–2.07) and
avoidance symptoms (OR: 1.42; 95%CI: 1.10–1.82) than
those with a single anxiety disorder. They experienced
more social disability compared with participants with a sin-
gle anxiety disorder (OR: 1.45; 95%CI: 1.16–1.98), but similar
rates of cognitive and physical disability. Participants with
anxiety–anxiety comorbidity did not receive significantly
more treatment (40.0% versus 30.8%; OR: 1.50; 95%CI:
0.94–2.37).
Unadjusted bivariate analyses show that participants with
anxiety–anxiety comorbidity more often had a positive fami-
ly history of anxiety or depressive disorders (63.8% versus
46.4%) compared with participants with a single anxiety dis-
order. Those with anxiety–anxiety comorbidity had higher
neuroticism levels and lower extraversion levels. The groups
did not differ critically with respect to age at the baseline in-
terview, childhood trauma, negative life events in the past
year and personality traits other than neuroticism and extra-
version. (Unadjusted statistics are not shown in the table.)
After adjusting for all covariates that were significant in
the bivariate analyses, the higher rate of positive family
history (OR: 2.07; 95%CI: 1.30–3.30) and the elevated neurot-
icism levels (OR: 1.51; 95%CI: 1.16–1.98) remained signifi-
cant, whereas the lower levels of extraversion were no
longer significant (OR: 0.83; 95%CI: 0.64–1.08).
3.3. Type of comorbidity
To investigate whether anxiety–anxiety comorbidity is
different from anxiety–depressive comorbidity with regard
to all of the aspects mentioned above, participants with
anxiety–anxiety comorbidity (n=105) were compared with
participants with anxiety–depressive comorbidity (n=292).
Participants with anxiety–anxiety comorbidity had an
earlier age of onset than those with anxiety–depressive co-
morbidity (19.3 years versus 22.6 years; OR: 1.33; 95%CI:
1.05–1.68) and a higher rate of chronic anxiety or depressive
symptoms (53.3% versus 41.4%; OR: 0.62; CI: 0.40–0.99). The
severity of anxiety and avoidance symptoms did not signifi-
cantly differ between the groups. The depressive symptoms
were however more severe among those with anxiety–
depressive comorbidity (OR: 2.09; 95%CI: 1.58–2.77). Those
with anxiety–depressive comorbidity had received significant-
ly more treatment (55.1% versus 40.0%; OR: 1.84; 95%CI:
1.17–2.90) and they also experienced more cognitive (OR:
1.88; 95%CI: 1.44–2.46), physical (OR: 1.34; 95%CI: 1.02–1.76)
and social disability (OR: 1.46; 95%CI: 1.13–1.89).
Like the unadjusted analyses, adjusted analyses show that
participants with anxiety–anxiety comorbidity more often
had a positive family history for anxiety or depressive
disorders (63.8% versus 45.9%; OR: 0.48; 95%CI: 0.30–0.76)
and elevated conscientiousness scores (OR: 0.77; 95%CI:
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between both types of comorbidity.3.4. Number of comorbid disorders
To investigate whether “double” comorbidity may be dis-
tinguished from anxiety–depressive comorbidity and anxi-
ety–anxiety comorbidity, clinical factors and risk-indicators
were compared. Both anxiety–anxiety comorbidity (n=105)
and anxiety–depressive comorbidity (n=292)were compared
with the group with double comorbidity (n=312). The differ-
ences found are presented in Tables 2 and 3.
Compared with anxiety–anxiety comorbidity, “double”
comorbidity was associated with more severe depressive
(OR: 4.52; 95%CI: 3.35–6.10), anxiety (OR: 2.15; 95%CI:
1.66–2.78) and avoidance symptoms (OR: 1.80; 95%CI:
1.42–2.29). Participants with “double” comorbidity also re-
ceived more treatment (70.8% versus 40.4%; OR: 3.64;
95%CI: 2.30–5.77) and experienced more disability in all do-
mains compared with anxiety–anxiety comorbidity.
Compared with anxiety–depressive comorbidity, “double”
comorbidity was associated with an earlier age of onset (18.0
versus 22.6 years; OR: 0.66; 95%CI: 0.59–0.77) and a higher
rate of chronicity (58.7% versus 41.4%; OR: 2.01; 95%CI:
1.45–2.77). Those with “double” comorbidity experienced
more severe depressive (OR: 2.16; 95%CI: 1.78–2.63), anxiety
(OR: 1.97; 95%CI: 1.65–2.35) and avoidance symptoms (OR:
2.01; 95%CI: 1.68–2.39). They also received more treatment
compared with those with anxiety–depressive comorbidity
(70.8% versus 55.1%; OR: 1.98; 95%CI: 1.41–2.77) and experi-
enced more disability in all domains.
The unadjusted bivariate models show that, compared
with those with anxiety–anxiety comorbidity, participants
with “double” comorbidity were less educated (10.9 versus
12.3 years) and were less likely to have a positive family his-
tory of anxiety or depressive disorders (52.6% versus 63.8%).
They were more likely to have experienced childhood trauma
(59.3% versus 40.4%) and negative life events in the past year
(0.8 versus 0.5 negative life events). Those with “double” co-
morbidity had elevated neuroticism and conscientiousness
levels and lower extraversion, openness and agreeableness
levels. (Unadjusted statistics are not shown in the Table).
After adjustment for all significant covariates in the bivariate
model, the lower level of education (OR: 0.91; 95%CI:
0.84–0.98), higher neuroticism levels (OR: 1.86; 95%CI:
1.38–2.49) and lower extraversion scores (OR: 0.67; 95%CI:
0.51–0.88) remained significantly different between those
with “double” comorbidity and those with anxiety–anxiety
comorbidity.
Comparing participants with “double” comorbidity with
those with anxiety–depressive comorbidity, unadjusted
models show that those with “double” comorbidity were
less educated (10.9 versus 11.8 years) and more likely to
have experienced childhood trauma (59.3% versus 51.0%).
They had elevated neuroticism levels and lower extraversion
and openness levels. After adjustment for all significant cov-
ariates in the bivariate model, the lower level of education
remained significantly different between those with “double”
comorbidity and those with anxiety–depressive comorbidity
(OR: 0.78; 95%CI: 0.65–0.93), as did the elevated neuroticism
111M. Klein Hofmeijer-Sevink et al. / Journal of Affective Disorders 137 (2012) 106–112levels (OR: 1.60; 95%CI: 1.30–1.97) and decreased extraver-
sion levels (OR: 0.79; 95%CI: 0.58–0.85).
4. Discussion
4.1. Clinical characteristics of comorbidity
In a well-defined subsample of the NESDA study of 1004
participants with at least one anxiety disorder, the clinical
relevance of comorbidity was studied. We may conclude
that both the type of comorbidity and the number of comor-
bid disorders are clinically important to diagnose.
Anxiety–anxiety comorbidity was associated with more se-
vere clinical characteristics comparedwith a single anxiety dis-
order. Patients with anxiety–anxiety comorbidity experienced
more severe symptoms, more chronic symptoms and more so-
cial impairment. It should be noted that in anxiety–anxiety co-
morbidity, not only anxiety symptoms were more severe,
depressive symptoms were also more severe. These findings
confirm an earlier finding of an association between anxiety–
anxiety comorbidity and severity of symptoms (Cougle et al.,
2010). The finding that anxiety–anxiety comorbidity is associ-
ated with more social impairment contradicts earlier research
that could not find an association between the number of
anxiety disorders and the quality of life (Barrera and Norton,
2009; Grant et al., 2005; Norberg et al., 2008).
Anxiety–anxiety comorbidity was associated with critically
different clinical factors comparedwith anxiety–depression co-
morbidity: The course of anxiety–anxiety comorbidity was
worse than the course of anxiety–depressive comorbidity,
with an earlier age of onset and more chronicity. Anxiety–
depressive comorbidity, however, is associated with more
treatment and higher levels of disability. These results suggest
that the type of comorbidity is important to diagnose, because
it differentiates anxiety–anxiety comorbidity from anxiety–
depressive comorbidity: the first type is more chronic, the
second type is more invalidating. “Double” comorbidity in anx-
iety disorders appeared to lead tomore severe symptoms,more
treatment and more day-to-day impairment compared with
anxiety–anxiety comorbidity or anxiety–depressive comorbid-
ity. This indicates that the number of diagnoses present is relat-
ed to severity, use of health care and negative consequences.
4.2. Sociodemographics and vulnerability factors of comorbidity
After adjusting for covariates, this study found that
neuroticism is the most consistent risk-indicator associated
with comorbidity in anxiety disorders. Neuroticism was
lowest in patients with a single anxiety disorder, higher in
patients with anxiety–anxiety comorbidity and anxiety–
depressive comorbidity and highest in those with double
comorbidity. This finding may not be specific for anxiety
disorders but may reflect general vulnerability given that
more psychiatric disorders are associated with high
neuroticism (Cox et al., 2004; Enns and Cox, 1997; van Os
and Jones, 2001). Ormel et al. (2004) argue that the associ-
ation of neuroticism and psychopathology is tautological,
since neuroticism reflects the presence of subthreshold
anxiety and depressed feelings over a period of time,
which obviously predict the development of an anxiety or
depressive disorder.4.3. Limitations and strengths
Several strengths and limitations should be taken into ac-
count. Strengths include the large sample size, the well-
implemented design of the NESDA study and the use of the
CIDI as a diagnostic instrument safeguarding statistical power
and the reliability of results. Limitations include the cross-
sectional design. A prospective design would be more appro-
priate to study the outcome. Another potential limitation of
this study is Post Traumatic Stress Disorder, Obsessive–
Compulsive Disorder and Specific Phobia were not assessed
in the NESDA study. Moreover, the single anxiety disorders
that were assessed were collapsed into one group to achieve
sufficient statistical power. If these disorders had had different
sociodemographics, vulnerability factors or clinical characteris-
tics, analyzing anxiety disorders as one group could have
resulted in a bias. Therefore, we have compared the specific
anxiety disorderswith each other (data not shown). All anxiety
disorders appeared to be similar. Based on this, we feel it is
justified to examine anxiety disorders as one group. Finally, in
this study no distinction was made between whether depres-
sion or anxiety disorder preceded the current anxiety disorder,
thus hampering establishment of whether or not comorbid de-
pression might be secondary to the anxiety disorder. However,
a recent study (Lamers et al., 2011) found nodifferences in clin-
ical characteristics between comorbidity with preceding de-
pression and comorbidity with preceding anxiety.
5. Conclusion
This study adds to current knowledge on comorbidity in
anxiety disorders. Its results clearly showed that it is impor-
tant to diagnose comorbidity among anxiety disorders as it
is associated with higher severity and more chronicity com-
pared with single anxiety disorders. In addition, it is also im-
portant to distinguish the type and number of comorbid
disorders: Whereas anxiety–anxiety comorbidity has an
earlier age of onset and a more chronic course, anxiety–
depressive comorbidity leads to more treatment and impaired
functioning. Furthermore, “double” comorbidity leads to even
more severity, chronicity and impairment compared with
both anxiety–anxiety and anxiety–depressive comorbidity.
These findings indicate that in clinical practice all comorbid dis-
orders present in patients with an anxiety disorder should be
diagnosed. Given the more severe symptomatology, unfavor-
able course and impaired functioning, patients with an anxiety
disorder and comorbid anxiety and depressive symptoms
should receive prompt and adequate treatment.
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